Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Historical perspective on current drugs for TB
4. TB timeline
5. Timeline: drugs for TB
6. Timeline: TB treatment development
7. Drugs for TB (WHO guidelines 2008) (1)
8. Drugs for TB (WHO guidelines 2008) (2)
9. Current regimens for treatment of TB
10. Latent versus active TB (1)
11. Recommended treatment regimens
12. Recommended 1st line regimen
13. Drug dosing (1)
14. Drug dosing (2)
15. Dosing frequency for new TB patients
16. Dosing frequency
17. Practical aspects of dosing
18. Sputum monitoring during treatment
19. Latent versus active TB (2)
20. Latent disease - treatment
21. Treatment principles
22. Extended multidrug therapy to cure TB (1)
23. Extended multidrug therapy to cure TB (2)
24. Drug profiles
25. Mechanism of action of 1st line drugs (1)
26. Mechanism of action of 1st line drugs (2)
27. Mechanism of action of 1st line drugs (3)
28. Isoniazid
29. Rifampicin
30. Pyrazinamide
31. Ethambutol
32. Streptomycin
33. Limitations of current therapy and special cases
34. Efficacy vs. effectiveness
35. Adherence
36. Summary of adverse events by drug
37. Side effects (minor)
38. Side effects (may be major)
39. Side effects (major)
40. Liver toxicity
41. Management of severe liver toxicity (1)
42. Management of severe liver toxicity (2)
43. Management of severe liver toxicity (3)
44. Drug resistance
45. Special situations
46. Special situations: extrapulmonary TB
47. Special situations: pregnancy and children
48. Special situations: liver/kidney disease
49. Special situations: HIV
50. Summary
51. Acknowledgements

Topics Covered

• Historical perspective
• Timeframe for drug and regimen development
• Current regimens
• Current WHO and ATS guidelines
• Treatment principles
• Pathological basis of action of TB drugs
• Drug profiles
• Limitations of current treatment regimens & special situations
• Problems with first line therapy
• Brief consideration of drug resistance

Links

Series:

• Respiratory Infection

Categories:

• Clinical Practice
• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on July 11, 2013

Financial Disclosures

• Dr. Kasha Singh has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.